Phage display antibody development is a versatile methodology that was introduced over 30 years ago. Until recently its high cost, labor intensive methods, and long development times made it a tool used almost exclusively for biologics development in large pharmaceutical and biotechnology companies. Today technology and method improvements developed at AxioMx make the phage display antibody development fast and cost-effective, and now applicable for broad use in life science antibody development.
AxioMx Technology Improvements Make Phage Display Antibody Development Fast and Cost-Effective and Now Applicable for Broad Use in Life Science Antibody Development.
Antibodies developed by phage-display are recombinant. At AxioMx our recombinant antibodies are single chain variable fragments (scFvs). ScFv antibodies are composed of immunoglobulin heavy and light chain genes connected by a short peptide linker. At AxioMx we often use the terms recombinant antibody and scFv interchangeably.
Recombinant antibodies, like scFvs, represent an attractive alternative to natural or traditional antibodies. They are epitope-specific and renewable through expression in the appropriate host. They can be genetically engineered with epitope tags, converted to IgGs, or further optimized to add or improve specific properties.
Advantages of recombinant antibodies relative traditional monoclonal and polyclonal antibodies include:
- Speed of development
- Consistency across production batches
- Versatility to design and engineer antibodies to requirements
- Optimization to further enhance properties
- All in vitro development